AVERSA™ Fentanyl Abuse Deterrent

AVERSA™ Transdermal Technology

Indication
Chronic Pain

Pre-Clinical

Phase I

NDA Filing

AVERSA™ Buprenorphine Abuse Deterrent

AVERSA™ Transdermal Technology

Indication
Chronic Pain

Pre-Clinical

Phase I

NDA Filing

AVERSA™ Methylphenidate

AVERSA™ Transdermal Technology

Indication
Attention Deficit Hyperactivity Disorder (ADHD)

Pre-Clinical

Phase I

NDA Filing

4P Exenatide​

Novel Transdermal

Indication
Type 2 Diabetes

Pre-Clinical

Phase I

Phase II

Phase III

NDA Filing

4P FSH

Novel Transdermal

Indication
Infertility

Pre-Clinical

Phase I

Phase II

Phase III

NDA Filing

Aversa™ abuse deterrent technology can be incorporated into any transdermal patch that has a risk of abuse.